At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open, Non-Interventional, Multicenter Trial of MabThera in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
In Brief
An observational study evaluating Cyclophosphamide, Hydroxydaunorubicin, and 3 other interventions for Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Completed, enrolled 154 participants across 5 sites.
Detailed Summary
Evaluation of efficacy, safety profile and tolerability of rituximab (MabThera) in combination with chemotherapy in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Participants, who were not treated previously for DLBCL, will receive MabThera in combination with Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) or CHOP-like chemotherapy according to registered indication. Patients will be followed up for safety and efficacy evaluation in accordance with routine practice. The study will be non-interventional and by its design purely observational. All treatments prescribed during the observation period will be at the treating physician's discretion and will be prescribed according to package labeling, within approved indication and local approval status of respective drugs.
Study Details
Timeline
Interventions
Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.